Company intelligence / Profile preview
Attovia Therapeutics
San Carlos, California, United Statesattovia.com ↗
- Ownership
- Private
- Development stage
- Preclinical
01
Overview
ATTO-1310 is currently in Phase 1 studies for chronic pruritus of unknown origin. ATTO-3712 is in IND-enabling phase with Phase 1 clinical studies planned for the second half of 2025.
- Therapeutic areas
- GastroenterologyImmunologyDermatology
- Modalities
- Biparatopic nanobodiesbispecific antibodiesmulti-specific biologics
- Industry
- Biotech
02
Drug pipeline
10 assets9 more assets in the full pipeline.
Request access →Beyond the preview
Go deeper on Attovia Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Attovia Therapeutics.